Scientific Industries (SCND) AI Stock Analysis

• Market Cap: $7.16M
• Dividend Yield: N/A
• Average Volume (3M): 12.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: -15.84%
• EPS Growth: 77.81%
• Country: US
• Employees: 61
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.34
• Shares Outstanding: 11,928,599
• 10 Day Avg. Volume: 13,652
• 30 Day Avg. Volume: 12,230
• PEG Ratio: 0.05
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 0.88
• P/FCF Ratio: -2.50
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 0.95
• Enterprise Value/Gross Profit: 2.29
• Enterprise Value/Ebitda: -12.82
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.50 ▼(-17.33% Downside)
• Action: Reiterated Date: 12/20/25
• Date: Action: Reiterated 12/20/25

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenues and cash flow challenges. Technical analysis indicates a bearish trend, and valuation metrics are unfavorable due to negative profitability and lack of dividends. These factors collectively result in a low stock score.

Positive Factors

Recognized flagship product (Vortex‑Genie)

The Vortex‑Genie’s strong recognition in biotech and pharma indicates durable product-market fit. A well-known flagship fosters repeat purchases, an installed base for aftermarket services, and differentiation versus peers, supporting steady demand and long-term revenue resilience.

Recurring services and distributor partnerships

A revenue mix of equipment sales plus maintenance, support services, and distributor channels diversifies income and reduces reliance on single transactions. Recurring service revenue and broader distribution increase resilience to product cycles and help sustain sales over multi‑month horizons.

Manageable leverage and stable equity ratio

The balance sheet’s moderate debt-to-equity and stable equity ratio suggest financial flexibility and a solid asset base. Manageable leverage supports capacity to fund operations, invest in product development, and withstand cyclical pressures without immediate refinancing stress.

Negative Factors

Declining revenue trend

Revenue contraction of roughly 15.8% signals weakening top-line momentum. Sustained declines impair operating leverage, reduce scale advantages, constrain R&D and commercial investment, and can erode market share unless reversed by product or channel improvements.

Negative profitability and shrinking margins

Persistent negative gross, EBIT and net margins indicate the business is not covering costs at scale. Continued unprofitability depletes retained earnings, limits reinvestment, and undermines long-term competitiveness unless structural cost or pricing improvements are achieved.

Weak cash generation and negative free cash flow

Negative operating and free cash flows constrain the company’s ability to fund capital needs, service debt, and invest in growth internally. Ongoing cash burn increases reliance on external financing and raises solvency and execution risks over the medium term.

Scientific Industries Business Overview & Revenue Model

Company Description

Scientific Industries, Inc. (SCND) is a leading provider of innovative laboratory equipment and solutions, primarily serving the biotechnology, pharmaceutical, and life sciences sectors. The company specializes in the design and manufacture of bioprocessing equipment, including its flagship product, the Vortex-Genie, which is widely recognized for its efficiency in mixing and sample preparation. Additionally, SCND offers a range of laboratory instruments and consumables that enhance research capabilities and streamline workflows for scientific professionals.

How the Company Makes Money

Scientific Industries generates revenue primarily through the sale of its bioprocessing equipment and laboratory instruments. Their revenue model is based on direct sales to end-users, including research institutions, pharmaceutical companies, and educational entities. Key revenue streams include the sale of laboratory mixers, vortex mixers, and other related products, as well as ongoing maintenance and support services for their equipment. The company also benefits from strategic partnerships with distributors who expand its market reach, along with potential licensing agreements for proprietary technologies that enhance their product offerings.

Scientific Industries Financial Statement Overview

Summary

Scientific Industries faces financial difficulties, with declining revenues, persistent losses, and cash flow challenges. While the balance sheet shows manageable leverage, the negative profitability and cash flow trends pose significant risks to financial stability.

Income Statement

Scientific Industries has experienced declining revenue growth with a negative trend in profitability. The gross profit margin has decreased over the years, and the company has been operating at a net loss, as indicated by the negative net profit margin. The EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage levels. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively stable, suggesting a solid asset base.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating and free cash flows. The free cash flow growth rate is negative, indicating cash flow deterioration. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting net income into cash.

Breakdown	TTM	Mar 2025	Mar 2024	Jun 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	8.95M	10.71M	11.11M	10.48M	9.78M	8.57M
Gross Profit	3.71M	4.73M	5.10M	4.64M	4.98M	3.85M
EBITDA	-662.10K	-5.89M	-8.51M	-7.41M	-4.46M	-979.00K
Net Income	-1.24M	-6.45M	-9.09M	-8.15M	-3.11M	-703.30K
Balance Sheet
Total Assets	14.56M	11.56M	16.73M	18.07M	29.01M	14.80M
Cash, Cash Equivalents and Short-Term Investments	8.29M	2.57M	5.72M	6.20M	13.42M	7.89M
Total Debt	820.00K	1.00M	1.33M	0.00	1.49M	1.47M
Total Liabilities	2.10M	2.44M	2.85M	3.28M	2.78M	3.08M
Stockholders Equity	12.46M	9.12M	13.89M	14.79M	26.22M	11.72M
Cash Flow
Free Cash Flow	-4.31M	-3.78M	-6.29M	-6.20M	-3.56M	-244.80K
Operating Cash Flow	-4.24M	-3.68M	-6.16M	-5.70M	-3.30M	-168.10K
Investing Cash Flow	2.88M	2.87M	-735.10K	3.61M	-10.88M	-84.10K
Financing Cash Flow	-3.17M	645.70K	5.75M	2.31M	16.31M	6.21M

Scientific Industries Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCND, the sentiment is Positive. The current price of 0.6 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 0.57, and below the 200-day MA of 0.67, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 77.11 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCND.

Scientific Industries Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
ELTK	51 Neutral	$56.68M	49.50	2.70%	2.16%	2.54%	-79.99%
SVRE	43 Neutral	$75.43M	>-0.01	-252.16%	―	16.11%	83.66%
SOBR	42 Neutral	$1.48M	-0.12	-203.38%	―	―	―
SCND	41 Neutral	$7.16M	-4.50	-65.40%	―	-15.84%	77.81%